Orthofix Medical Inc. (OFIX)
| Bid | 10.19 |
| Market Cap | 507.68M |
| Revenue (ttm) | 799.49M |
| Net Income (ttm) | -126M |
| EPS (ttm) | -3.3 |
| PE Ratio (ttm) | -3.94 |
| Forward PE | -19.13 |
| Analyst | Buy |
| Ask | 14.3 |
| Volume | 184,451 |
| Avg. Volume (20D) | 206,760 |
| Open | 13.10 |
| Previous Close | 12.96 |
| Day's Range | 12.88 - 13.20 |
| 52-Week Range | 12.08 - 20.73 |
| Beta | 1.00 |
About OFIX
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and append...
Analyst Forecast
According to 4 analyst ratings, the average rating for OFIX stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 84.47% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Orthofix Announces Appointment of Vickie Capps to Board of DirectorsLEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Director...
2 months ago · businesswire.com
Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal ConferenceLEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Canaccord Genuity 2025 Mu...
2 months ago · businesswire.com
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial ResultsLEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financi...